Margins proliferated in Q2
07/08/20 -"Despite the integration of BCN Pharma, Faes’ Q2 top-line came under pressure primarily due to the decline in sales of Bilastine (due to the reduction in pollen allergies). However, the momentum was ..."
Pages
45
Language
English
Published on
07/08/20
You may also be interested by these reports :
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...